Envista’s second quarter results were shaped by balanced growth across all major geographies and a continued focus on operational execution. Management pointed to resilient demand for dental care, especially in consumables and diagnostics, as a stabilizing influence despite macroeconomic uncertainty. CEO Paul Keel highlighted that new product launches in endodontics and orthodontics supported share gains, while margin expansion was driven by manufacturing productivity and cost control initiatives. The quarter also benefited from robust free cash flow conversion and ongoing progress in both reporting segments.
Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).
Envista (NVST) Q2 CY2026 Highlights:
- Revenue: $730.5 million vs analyst estimates of $716.3 million (7.1% year-on-year growth, 2% beat)
- Adjusted EPS: $0.41 vs analyst estimates of $0.34 (22.1% beat)
- Adjusted EBITDA: $107.7 million vs analyst estimates of $97.02 million (14.7% margin, 11% beat)
- Management raised its full-year Adjusted EPS guidance to $1.53 at the midpoint, a 8.9% increase
- Operating Margin: 11%, up from 6.8% in the same quarter last year
- Market Capitalization: $4.58 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Envista’s Q2 Earnings Call
-
Jonathan Block (Stifel): Asked if E&C segment growth was market-driven or due to company-specific share gains. CEO Paul Keel highlighted new product launches and share gains as primary factors.
-
Elizabeth Anderson (Evercore): Inquired about implant performance outside China and future product cadence. Keel emphasized balanced growth across geographies and upcoming new abutment launches.
-
Jeffrey Johnson (Baird): Asked about relative performance in Premium versus Challenger implant categories and future M&A strategy. Keel noted Challenger’s recent outperformance and a focus on targeted, accretive acquisitions.
-
Lilia-Celine Lozada (JPMorgan): Questioned the rationale behind moderating growth guidance for the year. CFO Eric Hammes cited billing day effects and normalization post-Spark deferral as key factors.
-
Kevin Caliendo (UBS): Sought clarity on China VBP’s long-term impact on volume and growth. Keel explained that short-term volume gains are likely, but longer-term growth will depend on sustained market investments and execution.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will watch (1) the execution of China’s VBP reforms and their effect on Envista’s market share and volume recovery, (2) progress of recently launched products in driving consumables and implant share gains, and (3) the stabilization of margins amid continued investments in R&D and commercial initiatives. The upcoming Investor Day will also serve as a key signpost for strategy updates and long-term priorities.
Envista currently trades at $28.62, in line with $28.63 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
